Wyeth, Karo Bio Stop Development Of LXR-623 For Atherosclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Another Liver X Receptor development duo, Exelixis and Bristol-Myers Squibb, extend their cardiovascular and metabolic drug development pact through January 2009.
You may also be interested in...
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.